Ribbon Acquisition Corp. Reports Q2 2026 Financial Results with Net Loss and Business Combination Update

Ribbon Acquisition Corp. has reported its financial results for the second quarter of 2026, revealing a net loss of $19,601 for the three months ending June 30, 2026, compared to a net income of $271,297 for the same period in 2025. For the first half of 2026, the company recorded a net income of $233,154, down from $507,153 in the prior year. The decline in profitability is attributed to increased operating expenses, which rose to $338,611 in Q2 2026 from $242,894 in Q2 2025, while income from marketable securities held in the Trust Account decreased to $319,010 from $514,191 year-over-year.

The company’s balance sheet as of June 30, 2026, shows total assets of $38.5 million, a significant decrease from $52.0 million at the end of 2025. This decline is primarily due to a reduction in cash and marketable securities held in trust, which fell from $51.9 million to $38.4 million. Current liabilities increased to $1.8 million from $607,002, driven by accrued expenses and a new promissory note of $902,938 issued to a related party. The company also reported an accumulated deficit of $374,868, up from $344,465 at the end of 2025.

In terms of strategic developments, Ribbon Acquisition Corp. is in the process of completing a business combination with DRC Medicine Ltd., a company specializing in AI-powered allergy and infection diagnostic kits. The business combination agreement was signed on June 30, 2025, and the company has until January 16, 2027, to finalize the deal. Shareholders approved an extension of the deadline in January 2026, allowing for monthly extension payments of $125,000 to be deposited into the trust account. As part of this process, 1,436,867 public shares were redeemed for a total of $14.9 million, reflecting shareholder confidence in the ongoing business combination efforts.

Operationally, Ribbon Acquisition Corp. has not yet commenced any revenue-generating activities, as it remains focused on the merger process. The company has incurred significant costs related to its public company status and the pursuit of the business combination, which it expects to continue. As of June 30, 2026, the company had a working capital deficit of $1.8 million and reported net cash used in operating activities of $88,766. The management has expressed concerns regarding the company's ability to continue as a going concern if the business combination is not completed within the specified timeframe.

Looking ahead, Ribbon Acquisition Corp. aims to leverage the funds held in the Trust Account for the business combination and to cover operational expenses. The company is actively seeking to finalize the merger with DRC Medicine and is preparing for the necessary regulatory approvals and shareholder votes. However, the management has acknowledged the uncertainty surrounding the completion of the business combination and the potential need for additional financing to support its operations.